Patients with intrahepatic CCA bear genetic alterations in FGFR2 and IDH1 mutations and benefit from matched targeted therapy [94], while in patients with extrahepatic CCA and GBC ERBB2 amplifications are more commonly identified [95]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.